EMPLOYER SPONSORED CLINIC - PRESCRIPTION DRUG
AMENDMENTS
2014 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Stewart Barlow
Senate Sponsor:
LONG TITLE
General Description:
This bill amends the Pharmacy Practice Act to exempt a prescribing practitioner from
its licensing requirements under certain circumstances.
Highlighted Provisions:
This bill:
<ul> <li>exempts a prescribing practitioner from the licensing requirements of the Pharmacy</li> </ul>
Practice Act if the prescribing practitioner dispenses a prepackaged drug at an
employer sponsored clinic and complies with other requirements;
<ul><li>repeals, subject to sunset review, the provisions of this bill relating to the exemption</li></ul>
described above; and
<ul><li>makes technical and conforming changes.</li></ul>
Money Appropriated in this Bill:
None
Other Special Clauses:
None
<b>Utah Code Sections Affected:</b>
AMENDS:
58-17b-301, as last amended by Laws of Utah 2013, Chapter 52
58-17b-302, as last amended by Laws of Utah 2013, Chapter 52



	58-17b-309, as last amended by Laws of Utah 2013, Chapter 278
	58-17b-309.5, as enacted by Laws of Utah 2012, Chapter 234
	63I-1-258, as last amended by Laws of Utah 2013, Chapters 55, 87, 222, 278, and 351
EN.	ACTS:
	<b>58-17b-309.7</b> , Utah Code Annotated 1953
Вез	it enacted by the Legislature of the state of Utah:
	Section 1. Section <b>58-17b-301</b> is amended to read:
	58-17b-301. License required License classifications for individuals.
	(1) A license is required to engage in the practice of pharmacy, telepharmacy, or the
prac	ctice of a pharmacy technician, except as specifically provided in Section 58-1-307,
58-	17b-309, [or] <u>58-17b-309.5</u> , 58-17-309.6, or <u>58-17b-309.7</u> .
	(2) The division shall issue to an individual who qualifies under this chapter a license
in tl	he classification of:
	(a) pharmacist;
	(b) pharmacy intern; or
	(c) pharmacy technician.
	Section 2. Section <b>58-17b-302</b> is amended to read:
	58-17b-302. License required License classifications for pharmacy facilities.
	(1) A license is required to act as a pharmacy, except as specifically exempted from
lice	nsure under Section 58-1-307 [or], 58-17b-309, 58-17b-309.5, 58-17-309.6, or
58-	<u>17b-309.7</u> .
	(2) The division shall issue a pharmacy license to a facility that qualifies under this
cha	pter in the classification of a:
	(a) class A pharmacy;
	(b) class B pharmacy;
	(c) class C pharmacy;
	(d) class D pharmacy; or
	(e) class E pharmacy.
	(3) Each place of business shall require a separate license. If multiple pharmacies exist
at tl	ne same address, a separate license shall be required for each pharmacy

02-05-14 1:22 PM H.B. 106

59	(4) The division may further define or supplement the classifications of pharmacies.		
60	The division may impose restrictions upon classifications to protect the public health, safety,		
61	and welfare.		
62	(5) Each pharmacy shall have a pharmacist-in-charge, except as otherwise provided by		
63	rule.		
64	(6) Whenever an applicable statute or rule requires or prohibits action by a pharmacy,		
65	the pharmacist-in-charge and the owner of the pharmacy shall be responsible for all activities		
66	of the pharmacy, regardless of the form of the business organization.		
67	Section 3. Section <b>58-17b-309</b> is amended to read:		
68	58-17b-309. Exemptions from licensure.		
69	(1) [For purposes of] As used in this section:		
70	(a) "Cosmetic drug":		
71	(i) means a prescription drug that is:		
72	(A) for the purpose of promoting attractiveness or altering the appearance of an		
73	individual; and		
74	(B) listed as a cosmetic drug subject to the exemption under this section by the division		
75	by administrative rule or has been expressly approved for online dispensing, whether or not it is		
76	dispensed online or through a physician's office; and		
77	(ii) does not include a prescription drug that is:		
78	(A) a controlled substance;		
79	(B) compounded by the physician; or		
80	(C) prescribed or used for the patient for the purpose of diagnosing, curing, or		
81	preventing a disease.		
82	(b) "Injectable weight loss drug":		
83	(i) means an injectable prescription drug:		
84	(A) prescribed to promote weight loss; and		
85	(B) listed as an injectable prescription drug subject to exemption under this section by		
86	the division by administrative rule; and		
87	(ii) does not include a prescription drug that is a controlled substance.		
88	(c) "Prescribing practitioner" means an individual licensed under:		
89	(i) Chapter 31b, Nurse Practice Act, as an advanced practice registered nurse with		

90	prescriptive practice;
91	(ii) Chapter 67, Utah Medical Practice Act;
92	(iii) Chapter 68, Utah Osteopathic Medical Practice Act; or
93	(iv) Chapter 70a, Physician Assistant Act.
94	(2) In addition to the exemptions from licensure in Sections 58-1-307 [and],
95	58-17b-309.5, <u>58-17b-309.6</u> , and <u>58-17b-309.7</u> , the following individuals may engage in the
96	acts or practices described in this section without being licensed under this chapter:
97	(a) [if the] an individual [is] described in Subsections (2)(b), (d), or (e), if the
98	individual notifies the division in writing of the individual's intent to dispense a drug under this
99	[subsection] Subsection (2);
100	(b) a person selling or providing contact lenses in accordance with Section 58-16a-801;
101	(c) an individual engaging in the practice of pharmacy technician under the direct
102	personal supervision of a pharmacist while making satisfactory progress in an approved
103	program as defined in division rule;
104	(d) a prescribing practitioner who prescribes and dispenses a cosmetic drug or an
105	injectable weight loss drug to the prescribing practitioner's patient in accordance with
106	Subsection (4); or
107	(e) an optometrist, as defined in Section 58-16a-102, acting within the optometrist's
108	scope of practice as defined in Section 58-16a-601, who prescribes and dispenses a cosmetic
109	drug to the optometrist's patient in accordance with Subsection (4).
110	(3) In accordance with Subsection 58-1-303(1)(a), an individual exempt under
111	Subsection (2)(c) must take all examinations as required by division rule following completion
112	of an approved curriculum of education, within the required time frame. This exemption
113	expires immediately upon notification of a failing score of an examination, and the individual
114	may not continue working as a pharmacy technician even under direct supervision.
115	(4) A prescribing practitioner or optometrist is exempt from licensing under the
116	provisions of this part if the prescribing practitioner or optometrist:
117	(a) (i) writes a prescription for a drug the prescribing practitioner or optometrist has the
118	authority to dispense under Subsection (4)(b); and

(A) that the prescription may be filled at a pharmacy or dispensed in the prescribing

119

120

(ii) informs the patient:

- 121 practitioner's or optometrist's office;
- (B) of the directions for appropriate use of the drug;
  - (C) of potential side-effects to the use of the drug; and
  - (D) how to contact the prescribing practitioner or optometrist if the patient has questions or concerns regarding the drug;
  - (b) dispenses a cosmetic drug or injectable weight loss drug only to the prescribing practitioner's patients or for an optometrist, dispenses a cosmetic drug only to the optometrist's patients;
  - (c) follows labeling, record keeping, patient counseling, storage, purchasing and distribution, operating, treatment, and quality of care requirements established by administrative rule adopted by the division in consultation with the boards listed in Subsection (5)(a); and
  - (d) follows USP-NF 797 standards for sterile compounding if the drug dispensed to patients is reconstituted or compounded.
  - (5) (a) The division, in consultation with the board under this chapter and the relevant professional board, including the Physician Licensing Board, the Osteopathic Physician Licensing Board, the Physician Assistant Licensing Board, the Board of Nursing, the Optometrist Licensing Board, or the Online Prescribing, Dispensing, and Facilitation Board, shall adopt administrative rules pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act to designate:
  - (i) the prescription drugs that may be dispensed as a cosmetic drug or weight loss drug under this section; and
    - (ii) the requirements under Subsection (4)(c).
  - (b) When making a determination under Subsection (1)(a), the division and boards listed in Subsection (5)(a) may consider any federal Food and Drug Administration indications or approval associated with a drug when adopting a rule to designate a prescription drug that may be dispensed under this section.
  - (c) The division may inspect the office of a prescribing practitioner or optometrist who is dispensing under the provisions of this section, in order to determine whether the prescribing practitioner or optometrist is in compliance with the provisions of this section. If a prescribing practitioner or optometrist chooses to dispense under the provisions of this section, the

152	prescribing practitioner or optometrist consents to the jurisdiction of the division to inspect the
153	prescribing practitioner's or optometrist's office and determine if the provisions of this section
154	are being met by the prescribing practitioner or optometrist.
155	(d) If a prescribing practitioner or optometrist violates a provision of this section, the
156	prescribing practitioner or optometrist may be subject to discipline under:
157	(i) this chapter; and
158	(ii) (A) Chapter 16a, Utah Optometry Practice Act;
159	(B) Chapter 31b, Nurse Practice Act;
160	(C) Chapter 67, Utah Medical Practice Act;
161	(D) Chapter 68, Utah Osteopathic Medical Practice Act;
162	(E) Chapter 70a, Physician Assistant Act; or
163	(F) Chapter 83, Online Prescribing, Dispensing, and Facilitation Licensing Act.
164	(6) Except as provided in Subsection (2)(e), this section does not restrict or limit the
165	scope of practice of an optometrist or optometric physician licensed under Chapter 16a, Utah
166	Optometry Practice Act.
167	Section 4. Section <b>58-17b-309.5</b> is amended to read:
168	58-17b-309.5. Exemption for prescribing practitioner of cancer drug regimen
169	Division study of dispensing practitioners.
170	(1) [For purposes of] As used in this section, "cancer drug treatment regimen":
171	(a) means a prescription drug used to treat cancer, manage its symptoms, or provide
172	continuity of care for a cancer patient;
173	(b) includes:
174	(i) a chemotherapy drug administered intravenously, orally, rectally, or by dermal
175	methods; and
176	(ii) a drug used to support cancer treatment, including to treat, alleviate, or minimize
177	physical and psychological symptoms or pain, or to improve patient tolerance of cancer
178	treatments or prepare a patient for a subsequent course of therapy; and
179	(c) does not mean a drug listed under federal law as a Schedule I, II, or III drug.
180	(2) In addition to the [exemption] exemptions from licensure under [Section] Sections
181	58-1-307, <u>58-17b-309</u> , <u>58-17b-309</u> .6, and <u>58-17b-309</u> .7, the following individuals are exempt

182

from licensure under this chapter:

	U2-U5-14 1:22 FWI H.D. 10
183	(a) an individual who:
184	(i) meets the requirements of Subsection (2)(b) or (c); and
185	(ii) notifies the division that the individual intends to dispense a cancer drug regimen
186	under this section;
187	(b) a prescribing practitioner who:
188	(i) treats a patient who is currently undergoing chemotherapy in an outpatient clinic
189	setting;
190	(ii) prescribes a cancer drug treatment regimen to the patient;
191	(iii) determines that providing the cancer drug treatment regimen to the patient in the
192	outpatient clinic setting is in the best interest of the patient, or provides better access to care for
193	the patient;
194	(iv) discloses to the patient that the cancer drug treatment regimen may be obtained
195	from a pharmacy unaffiliated with the prescribing practitioner and offers to the patient the
196	opportunity to consult with a pharmacist if the patient desires patient counseling;
197	(v) does not directly or indirectly mark up, charge a commission, or make a profit on
198	providing the cancer drug regimen, but may obtain payment for expenses and services related
199	to providing the cancer drug regimen;
200	(vi) provides the cancer drug treatment regimen to the patient, or directs another person
201	under Subsection (2)(c) to provide the cancer drug treatment regimen to the patient;
202	(vii) is certified or eligible to be certified by the American Board of Internal Medicine
203	in medical oncology;
204	(viii) reports to the Utah Controlled Substance Database in the same manner as
205	required by Section 58-37f-203, and follows labeling, recordkeeping, patient counseling,
206	purchasing and distribution, operating, treatment, quality of care, and storage requirements
207	established by administrative rule adopted by the division in consultation with the board; and
208	(ix) follows the USP-NF 797 standards for sterile compounding if the drug dispensed
209	to the patient is reconstituted or compounded; and

(c) a person who is not a prescribing practitioner who:

210

211

212213

(i) is employed as a health care provider by a prescribing practitioner or the outpatient clinic setting in which the prescribing practitioner works and is acting within the individual's scope of practice;

214	(ii) is acting under the direction of a prescribing practitioner who is immediately
215	available on site for any necessary consultation, and who has complied with Subsection
216	(2)(b)(i);
217	(iii) prepares or provides the cancer drug treatment regimen to the patient at the
218	outpatient clinic setting; and
219	(iv) follows Subsections (2)(b)(iv), (v), and (viii).
220	(3) (a) The division shall work with stakeholders to evaluate the exemptions to
221	licensure under this title in Subsections 58-17b-309(2)(b), (d), and (e) and this section.
222	(b) The evaluation under this Subsection (3) shall include:
223	(i) practitioner compliance with the requirements of this section and Section
224	58-17b-309;
225	(ii) current research on dispensing and patient safety;
226	(iii) survey of other state dispensing laws; and
227	(iv) recommendations for future action concerning practitioner dispensing.
228	(c) The division shall report to the Legislature's Health and Human Services Interim
229	Committee by November 30, 2012, and by November 30, 2013, with the results and
230	recommendations from the evaluation required by this Subsection (3).
231	(4) This section sunsets in accordance with Section 63I-1-258.
232	Section 5. Section <b>58-17b-309.7</b> is enacted to read:
233	58-17b-309.7. Exemption for a practitioner prescribing prepackaged drugs at an
234	employer sponsored clinic.
235	(1) As used in this section:
236	(a) "Employer sponsored clinic" means an entity that offers health care only to the
237	employees of an exclusive group of employers and the employees' dependents.
238	(b) "Health care" is as defined in Section 31A-1-301.
239	(c) "Prepackaged drug" means a prescription drug that:
240	(i) is not listed under federal or state law as a Schedule I, II, III, IV, or V drug; and
241	(ii) is packaged in a fixed quantity per package by:
242	(A) the drug manufacturer;
243	(B) a pharmaceutical wholesaler or distributor; or
244	(C) a pharmacy licensed under this title.

245	(d) "Prescribing practitioner" is as defined in Section 58-17b-309.
246	(2) In addition to the exemptions described in Sections 58-1-307, 58-17b-309,
247	58-17b-309.5, and 58-17b-309.6, a prescribing practitioner is exempt from the licensing
248	requirements of this chapter if the prescribing practitioner:
249	(a) treats an employee of one of an exclusive group of employers at an employer
250	sponsored clinic;
251	(b) prescribes a prepackaged drug to the employee;
252	(c) dispenses the prepackaged drug at the employer sponsored clinic;
253	(d) notifies the division:
254	(i) that the prescribing practitioner intends to dispense the prepackaged drug at the
255	employer sponsored clinic; and
256	(ii) of the drug the prescribing practitioner intends to dispense;
257	(e) determines that providing the prepackaged drug to the employee at the employer
258	sponsored clinic is in the employee's best interest;
259	(f) informs the employee:
260	(i) that the employee may obtain the drug prescribed by the prescribing practitioner
261	from a pharmacy that is unaffiliated with the prescribing practitioner;
262	(ii) of the directions for appropriate use of the prepackaged drug;
263	(iii) of potential side effects to the use of the prepackaged drug; and
264	(iv) how to contact the prescribing practitioner if the employee has questions or
265	concerns regarding the drug;
266	(g) offers the employee the opportunity to consult with a pharmacist if the employee
267	asks for patient counseling; and
268	(h) follows the administrative rules for a prescribing practitioner at an employer
269	sponsored clinic established by the division under Subsection (4).
270	(3) If the chapter that governs the license of a prescribing practitioner dispensing a
271	prepackaged drug under this section requires physician supervision in its scope of practice
272	requirements, the prescribing practitioner shall only dispense a prepackaged drug under the
273	supervision of an individual licensed under Chapter 67, Utah Medical Practice Act, or Chapter
274	68, Utah Osteopathic Medical Practice Act.
275	(4) The division shall, in consultation with the board of pharmacy and the Physicians

276	<u>Licensing Board created in Section 58-67-201</u> , adopt administrative rules pursuant to Title
277	63G, Chapter 3, Utah Administrative Rulemaking Act, that establish labeling, record keeping,
278	patient counseling, purchasing and distribution, operating, treatment, quality of care, and
279	storage requirements for a prescribing practitioner at an employer sponsored clinic.
280	(5) The division may inspect the office of a prescribing practitioner who is dispensing a
281	prepackaged drug at an employer sponsored clinic to determine whether the prescribing
282	practitioner is in compliance with this section.
283	(6) If a prescribing practitioner violates a provision of this section, the prescribing
284	practitioner may be subject to discipline under:
285	(a) this chapter; and
286	(b) any other chapter that governs the terms of the prescribing practitioner's license.
287	(7) The division shall evaluate the exemption created by this section and report to the
288	Legislature's Health and Human Services Interim Committee by July 1, 2016, and by July 1,
289	2018, on the results of the evaluation and the division's recommendations regarding the
290	exemption.
291	Section 6. Section <b>63I-1-258</b> is amended to read:
292	63I-1-258. Repeal dates, Title 58.
293	(1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is
294	repealed July 1, 2016.
295	(2) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2015.
296	(3) Section 58-17b-309.5 is repealed July 1, 2015.
297	(4) Section 58-17b-309.7 is repealed on July 1, 2018.
298	[(4)] (5) Title 58, Chapter 20a, Environmental Health Scientist Act, is repealed July 1,
299	2018.
300	[(5)] (6) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1,
301	2023.
302	[(6)] (7) Title 58, Chapter 41, Speech-language Pathology and Audiology Licensing
303	Act, is repealed July 1, 2019.
304	[ <del>(7)</del> ] (8) Title 58, Chapter 42a, Occupational Therapy Practice Act, is repealed July 1,
305	2015.
306	[ <del>(8)</del> ] (9) Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act, is

307	repeale	d July 1, 2023.
308		[ <del>(9)</del> ] <u>(10)</u> Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed July 1,
309	2014.	
310		[ <del>(10)</del> ] <u>(11)</u> Section 58-69-302.5 is repealed on July 1, 2015.

[(11)] (12) Title 58, Chapter 72, Acupuncture Licensing Act, is repealed July 1, 2017.

Legislative Review Note as of 2-3-14 4:18 PM

02-05-14 1:22 PM

311

Office of Legislative Research and General Counsel

H.B. 106